AstraZeneca Files 2025 Annual Report Ahead of April 2026 AGM
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
AstraZeneca ( (GB:AZN) ) just unveiled an update.
AstraZeneca has published its 2025 Annual Report and Form 20-F Information, making the document available via the U.K. National Storage Mechanism and on the company’s website, with hard copies to be dispatched to shareholders in due course. The filing, prepared to meet disclosure and transparency requirements, includes unedited details on principal risks and uncertainties, directors’ responsibility statements and related-party transactions, ahead of the company’s annual general meeting scheduled for 9 April 2026, underscoring its ongoing regulatory compliance and governance transparency for investors and other stakeholders.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £16781.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
Spark’s Take on GB:AZN Stock
According to Spark, TipRanks’ AI Analyst, GB:AZN is a Outperform.
The score is driven primarily by strong underlying financial performance and a constructive earnings outlook (growth guidance and pipeline progress). This is tempered by valuation (P/E ~30), recent free-cash-flow variability, and technical signals that appear overextended despite the broader uptrend.
To see Spark’s full report on GB:AZN stock, click here.
More about AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company based in Cambridge, U.K., specialising in the discovery, development and commercialisation of prescription medicines. Its core areas are Oncology, Rare Diseases and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology, with products sold in more than 125 countries to millions of patients worldwide.
Average Trading Volume: 2,384,331
Technical Sentiment Signal: Buy
Current Market Cap: £241B
Find detailed analytics on AZN stock on TipRanks’ Stock Analysis page.
